Article
Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism.
Annals of hepatology - 1 Jan 2000
Federico Alessandro, Aitella Ernesto, Sgambato Dolores, Savoia Alfonso, De Bartolomeis Fabio, Dallio Marcello, Ruocco Eleonora, Pezone Luciano, Abbondanza Ciro, Loguercio Carmela, Astarita Corrado
Abstract excerpt
The HCV protease inhibitor telaprevir associated with peginterferon-alpha and ribavirin, was widely used in the recent past as standard treatment in HCV genotype-1 infected patients. Telaprevir improves the sustained virology response rates, but at the same time increases the frequency of adverse cutaneous reactions. However, mechanisms through which telaprevir induces cutaneous lesions are not yet defined. A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.